|
|
|
|
|
|
|
|
|
|
| due to the recent operational progress and the significantly increased interest from investors, the financing round of HKK Bionics will be reopened for a short time this week. |
|
|
|
|
|
|
The trigger for the restart is the successful realignment of HKK Bionics towards centrally and digitally manufactured orthoses, which will already show a noticeable effect in the first weeks of 2026.
There is also a clear dynamic in sales: Ten product presentations have already been carried out with potential new customers, and further appointments are planned. This development is supplemented by a significant order backlog with open orders and approved supplies in the six-figure range.
Read more about the current progress and next steps of HKK Bionics in the update from founder Dominik Hepp. |
|
|
|
|
|
|
|
|
| INVESTMENT HIGHLIGHTS |
|
|
|
|
| • |
|
Technology and market leadership: MedTech “Made in Germany” – secured by patents. |
|
|
| • |
|
Growth: Over EUR 1 million in 2025. |
|
|
| • |
|
Broad customer base: Over 60 medical supply stores in DE & AT are already customers. |
|
|
| • |
|
Customer potential: Digital central manufacturing enables 1,000% more new customers. |
|
|
| • |
|
Strong sales network to doctors, therapists and medical supply stores. |
|
|
| • |
|
Exit plans are becoming more concrete: With break-even at the end of 2026, ongoing discussions can be intensified. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Companisto GmbH |
|
Köpenicker Str. 154, 10997 Berlin
Managing Director: Tamo Zwinge, LL. M. and David Rhotert
Amtsgericht: Berlin Charlottenburg HRB 132811 B
VAT-ID: DE 276 014 929
Phone: +49 30 330 837 49
Email: service@companisto.com |
|
|
|
|
|
|
|
|
| You receive this newsletter because you have subscribed to it. You can unsubscribe at any time via the unsubscribe link. |
|
| The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity. |
|
|
|
|
